C83.3 Diffuse large B-cell lymphoma

Name of the Condition

• Diffuse Large B-Cell Lymphoma (ICD-10 Code: C83.3)

Summary

Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma that originates in B-cells, a type of white blood cell. It is characterized by rapidly growing tumors in the lymph nodes or other lymphoid tissues. DLBCL is one of the most common subtypes of non-Hodgkin lymphoma and can occur in various parts of the body.

Causes

The exact cause of DLBCL is not fully understood. It is believed to result from genetic mutations in B-cells, which may be triggered by factors such as previous infections (e.g., Epstein-Barr virus), immune system dysfunctions, or exposure to certain environmental agents. These mutations disrupt normal cell growth and division, leading to uncontrolled proliferation.

Risk Factors

• Advanced age (most common in older adults)
• Weakened immune system (e.g., from HIV, organ transplants, or immunosuppressive drugs)
• Family history of lymphoma
• Exposure to certain chemicals or radiation
• Chronic infections (e.g., hepatitis C)

Symptoms

• Swollen, painless lymph nodes (most often in the neck, armpit, or groin)
• Unexplained weight loss
• Fever
• Night sweats
• Fatigue
• Loss of appetite
• Shortness of breath or chest pain (if lymph nodes in the chest are affected)

Diagnosis

Diagnosis involves a combination of physical examination, imaging tests (e.g., CT or PET scans) to identify affected areas, biopsy of lymph nodes or tissues for laboratory analysis, and blood tests to assess overall health and detect abnormal cell markers. A definitive diagnosis requires histopathological examination to confirm the presence of large, abnormal B-cells.

Treatment Options

• Chemotherapy: The primary treatment, often using regimens like R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone).
• Immunotherapy: Monoclonal antibodies (e.g., rituximab) to target cancer cells.
• Radiation therapy: Used for localized disease or to reduce tumor size before other treatments.
• Stem cell transplant: Considered for relapsed or refractory cases.

Prognosis and Follow-Up

DLBCL is aggressive but often responsive to treatment, especially when diagnosed early. Prognosis depends on factors like age, overall health, and disease stage. Regular follow-up with imaging and blood tests is essential to monitor for recurrence or complications.

Complications

• Tumor lysis syndrome (due to rapid cell death during treatment)
• Infection risk from weakened immune system
• Organ damage (e.g., to kidneys or liver)
• Relapse or progression to other lymphoma types

Lifestyle & Prevention

• Maintain a healthy immune system through balanced nutrition and regular exercise.
• Avoid exposure to known carcinogens (e.g., pesticides, radiation).
• Manage chronic infections promptly.
• Seek medical care for persistent lymph node swelling or unexplained symptoms.

When to Seek Professional Help

Consult a healthcare provider if you experience persistent swollen lymph nodes, unexplained weight loss, fever, or night sweats. Early evaluation is critical for timely diagnosis and treatment.

Tips for Medical Coders

• Use code C83.3 for diffuse large B-cell lymphoma when the condition is documented without additional site specification.
• Ensure documentation supports the diagnosis, including histopathological confirmation of large B-cell morphology.
• Avoid using this code for other lymphoma subtypes (e.g., follicular lymphoma) or site-specific variants (e.g., intra-abdominal or multiple-site DLBCL).
• Verify that the code aligns with the clinical scenario and does not conflict with more specific codes if applicable.